Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
i.SigNal is Dreamtech’s digital healthcare brand and operating organization focused on medical devices and digital cardiac monitoring. The business is centered on wearable electrocardiogram monitoring solutions, most notably Cardea SOLO, a single-use ambulatory ECG patch paired with proprietary analysis software for arrhythmia detection and diagnosis. i.SigNal has operated commercially in South Korea and has held distribution rights for Cardea SOLO across multiple Asia-Pacific markets. Based on available public information, the company appears to function primarily as a digital health and medtech commercialization vehicle rather than a therapeutic drug developer. Its activities are concentrated in cardiac diagnostics, remote/wearable monitoring, regulatory approvals, and regional distribution.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on i.SigNal.